Literature DB >> 27181403

Divergent Inflammatory, Fibrogenic, and Liver Progenitor Cell Dynamics in Two Common Mouse Models of Chronic Liver Injury.

Julia Köhn-Gaone1, Benjamin J Dwyer1, Candice A Grzelak2, Gregory Miller3, Nicholas A Shackel4, Grant A Ramm5, Geoffrey W McCaughan6, Caryn L Elsegood7, John K Olynyk8, Janina E E Tirnitz-Parker9.   

Abstract

Complications of end-stage chronic liver disease signify a major cause of mortality worldwide. Irrespective of the underlying cause, most chronic liver diseases are characterized by hepatocellular necrosis, inflammation, fibrosis, and proliferation of liver progenitor cells or ductular reactions. Vast differences exist between experimental models that mimic these processes, and their identification is fundamental for translational research. We compared two common murine models of chronic liver disease: the choline-deficient, ethionine-supplemented (CDE) diet versus thioacetamide (TAA) supplementation. Markers of liver injury, including serum alanine transaminase levels, apoptosis, hepatic fat loading, and oxidative stress, as well as inflammatory, fibrogenic and liver progenitor cell responses, were assessed at days 3, 7, 14, 21, and 42. This study revealed remarkable differences between the models. It identified periportal injury and fibrosis with an early peak and slow normalization of all parameters in the CDE regimen, whereas TAA-treated mice had pericentral patterns of progressive injury and fibrosis, resulting in a more severe hepatic injury phenotype. This study is the first to resolve two different patterns of injury and fibrosis in the CDE and TAA model and to indisputably identify the fibrosis pattern in the TAA model as driven from the pericentral vein region. Our data provide a valuable foundation for future work using the CDE and TAA regimens to model a variety of human chronic liver diseases.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27181403     DOI: 10.1016/j.ajpath.2016.03.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  11 in total

1.  Biomechanical assessment of chronic liver injury using quantitative micro-elastography.

Authors:  Alireza Mowla; Rose Belford; Julia Köhn-Gaone; Nathan Main; Janina E E Tirnitz-Parker; George C Yeoh; Brendan F Kennedy
Journal:  Biomed Opt Express       Date:  2022-09-01       Impact factor: 3.562

2.  The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles.

Authors:  Yunfang Li; Wenting Shang; Xiaoyuan Liang; Chaoting Zeng; Mingming Liu; Sudan Wang; Hongjun Li; Jie Tian
Journal:  RSC Adv       Date:  2018-02-12       Impact factor: 4.036

3.  Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing.

Authors:  Christine N Goldfarb; Kritika Karri; Maxim Pyatkov; David J Waxman
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

Review 4.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

5.  The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury.

Authors:  Jully Gogoi-Tiwari; Julia Köhn-Gaone; Corey Giles; Dirk Schmidt-Arras; Francis D Gratte; Caryn L Elsegood; Geoffrey W McCaughan; Grant A Ramm; John K Olynyk; Janina E E Tirnitz-Parker
Journal:  J Vis Exp       Date:  2017-10-21       Impact factor: 1.355

6.  Transdifferentiation of pancreatic progenitor cells to hepatocyte-like cells is not serum-dependent when facilitated by extracellular matrix proteins.

Authors:  Francis D Gratte; Sara Pasic; John K Olynyk; George C T Yeoh; David Tosh; Deirdre R Coombe; Janina E E Tirnitz-Parker
Journal:  Sci Rep       Date:  2018-03-12       Impact factor: 4.379

7.  Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis.

Authors:  Shinya Tsurusaki; Yuichi Tsuchiya; Tomoko Koumura; Misaki Nakasone; Taro Sakamoto; Masaki Matsuoka; Hirotaka Imai; Cindy Yuet-Yin Kok; Hitoshi Okochi; Hiroyasu Nakano; Atsushi Miyajima; Minoru Tanaka
Journal:  Cell Death Dis       Date:  2019-06-18       Impact factor: 8.469

8.  Hepatic progenitor cell activation is induced by the depletion of the gut microbiome in mice.

Authors:  Fei Wang; Nan-Nan Sun; Lan-Lan Li; Wan-Wan Zhu; Jianbo Xiu; Yan Shen; Qi Xu
Journal:  Microbiologyopen       Date:  2019-05-16       Impact factor: 3.139

9.  A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.

Authors:  Robin D Tucker; Victor Ciofoaia; Sandeep Nadella; Martha D Gay; Hong Cao; Matthew Huber; Anita Safronenka; Narayan Shivapurkar; Bhaskar Kallakury; Annie J Kruger; Alexander H K Kroemer; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-07-11       Impact factor: 3.199

Review 10.  Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models.

Authors:  Marina Galicia-Moreno; Jorge A Silva-Gomez; Silvia Lucano-Landeros; Arturo Santos; Hugo C Monroy-Ramirez; Juan Armendariz-Borunda
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.